Generic Company Disclosure Could Be A 'Speedbump' Against Misuse Of US FDA Access Inquiry List

 
• By Sue Sutter
  
photographed close-up of road marking is located on the roadway, warning of the presence of the hump
FDA may look to slow any potential generic company rush to use the public list of reference listed drug inquiries to shame brand companies.

More from Generics

More from Biosimilars & Generics